category,datetime,headline,id,image,related,source,summary,url
company,1768496156,Dividend King Abbott Shows Why 52 Consecutive Increases Weren’t Luck With Strong Cash Flow Coverage,138126438,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,ABT,Yahoo,"Abbott Laboratories (NYSE: ABT) doesn’t just pay dividends. It grows them. For 52 consecutive years. That’s Dividend King territory, and the streak isn’t in danger. The company just raised its quarterly dividend to $0.63 in January 2026, a 6.8% increase from the prior $0.59 rate. That puts the annual payout at $2.52 per share with ... Dividend King Abbott Shows Why 52 Consecutive Increases Weren’t Luck With Strong Cash Flow Coverage",https://finnhub.io/api/news?id=1efa10e9cb234652eae54435b33fde1e0b6452547cd96ec10b441a225413b784
company,1768479722,Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade,138120717,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,ABT,Yahoo,"Jan 15 (Reuters) - Boston Scientific is buying medical equipment maker Penumbra in a deal valued at about $14.5 billion, to expand its vascular pipeline.",https://finnhub.io/api/news?id=bbfd391d9f8f10e71e49dace0086a3bd81f1b55ce02d42df5ea273c7dd6618c5
company,1768474920,Boston Scientific is buying Penumbra for $14.5 billion to get into the business of removing blood clots,138144982,,ABT,MarketWatch,Boston Scientific is buying Penumbra for $14.5 billion to get into the business of removing blood clots,https://finnhub.io/api/news?id=5f86d86ba9f797cb587b2ac18b2dfb0eb684896eabaf26d47609f2c0a2a01c0d
